중증 인플루엔자 치료 지침

키워드

참고문헌 (88)

1. 최원석, "계절 인플루엔자의 항바이러스제 사용 지침", Infection and Chemotherapy, 44(4), pp.233~249 (2012), 대한감염학회
2. "WHO guidelines for pharmacological management of pandemic influenza A(H1N1) 2009 and other influenza viruses" (2013)[URL]
3. Hayden FG, "Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment", JAMA, 282, pp.1240~1246 (1999)
4. Kohno S, "Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients", Antimicrob Agents Chemother, 55, pp.2803~2812 (2011)
5. Nicholson KG, "Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial: Neuraminidase Inhibitor Flu Treatment Investigator Group", Lancet, 355, pp.1845~1850 (2000)
6. Treanor JJ, "Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial: US Oral Neuraminidase Study Group", JAMA, 283, pp.1016~1024 (2000)
7. Yang SG, "Antiviral therapy and outcomes of patients with pneumonia caused by influenza A pandemic (H1N1) virus", PLoS One, 7, pp.e29652~ (2012)
8. South East Asia Infectious Disease Clinical Research Network, "Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial", BMJ, 346, pp.f3039~ (2013)
9. Lee N, "A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza a and B infections", Clin Infect Dis, 57, pp.1511~1519 (2013)
10. Kim AR, "A case of high dose oseltamivir treatment in an influenza A(H1N1) infected patient with severe graft versus host disease", Clin Pediatr Hematol Oncol, 18, pp.58~61 (2011)
11. Kang SJ, "Virological clearance rate of high-dose oseltamivir or triple-combination antiviral therapy in complicated 2009 pandemic influenza A(H1N1) infection", Jpn J Infect Dis, 66, pp.425~427 (2013)
12. Leekha S, "Duration of influenza A virus shedding in hospitalized patients and implications for infection control", Infect Control Hosp Epidemiol, 28, pp.1071~1076 (2007)
13. Fiore AE, "Antiviral agents for the treatment and chemoprophylaxis of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP)", MMWR Recomm Rep, 60, pp.1~24 (2011)
14. Escuret V, "Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections", Antiviral Res, 96, pp.130~137 (2012)
15. Duval X, "Efficacy of oseltamivir- zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial", PLoS Med, 7, pp.e1000362~ (2010)
16. Smee DF, "Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice", Antimicrob Agents Chemother, 53, pp.2120~2128 (2009)
17. Nguyen JT, "Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro", Antimicrob Agents Chemother, 53, pp.4115~4126 (2009)
18. Kim WY, "Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation", Antimicrob Agents Chemother, 55, pp.5703~5709 (2011)
19. Fraaij PL, "Evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic influenza A(H1N1) infection", J Infect Dis, 204, pp.777~782 (2011)
20. Petersen E, "Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator- and ECMO-treated critically ill patients with pandemic influenza A(H1N1)v", Scand J Infect Dis, 43, pp.495~503 (2011)
21. Del Mar CB, "Antibiotics for sore throat", Cochrane Database Syst Rev, 2, pp.CD000023~ (2004)
22. Smucny J, "Antibiotics for acute bronchitis", Cochrane Database Syst Rev, 4, pp.CD000245~ (2004)
23. Spurling GK, "Delayed antibiotics for respiratory infections", Cochrane Database Syst Rev, 4, pp.CD004417~ (2013)
24. Morciano C, "Italian evidencebased guidelines for the management of influenza-like syndrome in adults and children", Ann Ist Super Sanita, 45, pp.185~192 (2009)
25. Centers for Disease Control and Prevention (CDC)., "Surveillance for pediatric deaths associated with 2009 pandemic influenza A(H1N1) virus infection-United States, April- August 2009", MMWR Morb Mortal Wkly Rep, 58, pp.941~947 (2009)
26. Wright PF, "When to consider the use of antibiotics in the treatment of 2009 H1N1 influenza- associated pneumonia", N Engl J Med, 361, pp.e112~ (2009)
27. 송재훈, "지역사회획득 폐렴의 치료지침 권고안", Infection and Chemotherapy, 41(3), pp.133~153 (2009), 대한감염학회
28. "Korean Clinical Practice Guideline: Otitis Media in Children 2010" (2010)[URL]
29. Paden ML, "Thiagarajan RR; ELSO Registry. Extracorporeal life support organization registry report 2012", ASAIO J, 59, pp.202~210 (2012)
30. Sadahiro T, "Trends in and perspectives on extracorporeal membrane oxygenation for severe adult respiratory failure", Gen Thorac Cardiovasc Surg, 60, pp.192~201 (2012)
31. Rodriguez A, "Recommendations of the Infectious Diseases Work Group (GTEI) of the Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC) and the Infections in Critically III Patients Study Group (GEIPC) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) for the diagnosis and treatment of influenza A", H1N1 in seriously ill adults admitted to the Intensive Care Unit, 2012, pp.36, 103~137
32. Michaels AJ, "Pandemic flu and the sudden demand for ECMO resources: a mature trauma program can provide surge capacity in acute critical care crises", J Trauma Acute Care Surg, 74, pp.1493~1497 (2013)
33. Zangrillo A, "Extracorporeal membrane oxygenation (ECMO) in patients with H1N1 influenza infection: a systematic review and metaanalysis including 8 studies and 266 patients receiving ECMO", Crit Care, 17, pp.R30~ (2013)
34. Pappalardo F, "Predicting mortality risk in patients undergoing venovenous ECMO for ARDS due to influenza A(H1N1) pneumonia: the ECMOnet score", Intensive Care Med, 39, pp.275~281 (2013)
35. Takeda S, "Extracorporeal membrane oxygenation for 2009 influenza A(H1N1) severe respiratory failure in Japan", J Anesth, 26, pp.650~657 (2012)
36. Roncon-Albuquerque R Jr, "Portable miniaturized extracorporeal membrane oxygenation systems for H1N1-related severe acute respiratory distress syndrome: a case series", J Crit Care, 27, pp.454~463 (2012)
37. Brink M, "Respiratory support during the influenza A(H1N1) pandemic flu in Sweden", Acta Anaesthesiol Scand, 56, pp.976~986 (2012)
38. Hou X, "Extracorporeal membrane oxygenation for critically ill patients with 2009 influenza A(H1N1)-related acute respiratory distress syndrome: preliminary experience from a single center", Artif Organs, 36, pp.780~786 (2012)
39. Shetty AK, "Oseltamivir-resistant 2009 H1N1 influenza pneumonia during therapy in a renal transplant recipient", Pediatr Transplant, 16, pp.E153~157 (2012)
40. 손장원, "Critical Care Paper Review 2012", Tuberculosis and Respiratory Diseases, 73(1), pp.1~10 (2012), 대한결핵및호흡기학회[DOI]
41. Morgan CI, "2009 pandemic influenza A(H1N1) in critically ill children in Cincinnati, Ohio", Pediatr Crit Care Med, 13, pp.e140~144 (2012)
42. Bonastre J, "Extracorporeal lung support in patients with severe respiratory failure secondary to the 2010-2011 winter seasonal outbreak of influenza A(H1N1) in Spain", Med Intensiva, 36, pp.193~199 (2012)
43. Lemaitre F, "Impact of extracorporeal membrane oxygenation and continuous venovenous hemodiafiltration on the pharmacokinetics of oseltamivir carboxylate in critically ill patients with pandemic (H1N1) influenza", Ther Drug Monit, 34, pp.171~175 (2012)
44. Beurtheret S, "Extracorporeal membrane oxygenation for 2009 influenza A(H1N1) acute respiratory distress syndrome: single-centre experience with 1-year follow-up", Eur J Cardiothorac Surg, 41, pp.691~695 (2012)
45. Azevedo LC, "Extracorporeal membrane oxygenation in severe hypoxemia: time for reappraisal", J Bras Pneumol, 38, pp.7~12 (2012)
46. Li HL, "The application of extracorporeal membrane oxygenation in critically ill patient", Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, 24, pp.86~89 (2012)
47. Van Ierssel SH, "Severe influenza A(H1N1)2009 infection: a single centre experience and review of the literature", Acta Clin Belg, 67, pp.1~6 (2012)
48. 지선태, "2009 H1N1 influenza virus infection and necrotizing pneumonia treated with extracorporeal membrane oxygenation", Korean Journal of Pediatrics, 54(8), pp.345~349 (2011), 대한소아과학회
49. 이경학, "대유행 인플루엔자(H1N1 2009) 급성호흡곤란증후군에 대한 체외막 산소화 장치의 조기적용 1례", Infection and Chemotherapy, 42(2), pp.122~126 (2010), 대한감염학회
50. Dominguez-Cherit G, "Critically Ill patients with 2009 influenza A(H1N1) in Mexico", JAMA, 302, pp.1880~1887 (2009)
51. Quispe-Laime AM, "H1N1 influenza A virus-associated acute lung injury: response to combination oseltamivir and prolonged corticosteroid treatment", Intensive Care Med, 36, pp.33~41 (2010)
52. Kil HR, "Early corticosteroid treatment for severe pneumonia caused by 2009 H1N1 influenza virus", Crit Care, 15, pp.413~ (2011)
53. 손유락, "소아에서 2009 신종 인플루엔자 A (H1N1) 중증 폐렴과 스테로이드 치료", Pediatric Infection and Vaccine, 18(2), pp.193~200 (2011), 대한소아감염학회
54. Confalonieri M, "Corticosteroids do not cause harmful increase of viral load in severe H1N1 virus infection", Intensive Care Med, 36, pp.1780~1781 (2010)
55. Confalonieri M, "Methylprednisolone infusion for life-threatening H1N1-virus infection", Ther Adv Respir Dis, 4, pp.233~237 (2010)
56. Ohtsuki N, "Effects of mild hypothermia and steroid pulse combination therapy on acute encephalopathy associated with influenza virus infection: report of two cases", No To Hattatsu, 32, pp.318~322 (2000)
57. Hibino M, "A case of acute respiratory distress syndrome associated with pandemic influenza A(H1N1) pneumonia which was aggravated by the cessation of corticosteroid therapy", Nihon Kokyuki Gakkai Zasshi, 49, pp.955~963 (2011)
58. Samejima T, "Case of novel influenza A(H1N1) pneumonia with shrinkage of a pulmonary lesion", Nihon Kokyuki Gakkai Zasshi, 48, pp.930~937 (2010)
59. Ishiguro T, "Two patients with novel influenza A virus (H1N1) pneumonia treated with steroid therapy after an incorrect diagnosis of rapid progressive interstitial pneumonia due to the negative results of a rapid-antigen test", Nihon Kokyuki Gakkai Zasshi, 48, pp.687~695 (2010)
60. Sakurai T, "Case of adult influenza type A virus-associated encephalopathy successfully treated with primary multidisciplinary treatments", Rinsho Shinkeigaku, 47, pp.639~643 (2007)
61. Djibre M, "Non-invasive management of acute respiratory distress syndrome related to Influenza A(H1N1) virus pneumonia in a pregnant woman", Intensive Care Med, 36, pp.373~374 (2010)
62. Ando M, "Virus associated hemophagocytic syndrome accompanied by acute respiratory failure caused by influenza A (H3N2)", Intern Med, 45, pp.1183~1186 (2006)
63. Athauda D, "Multiphasic acute disseminated encephalomyelitis (ADEM) following influenza type A (swine specific H1N1)", J Neurol, 259, pp.775~778 (2012)
64. Wang Y, "Treatment of critically ill influenza A H1N1 patients in plateau region", Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, 22, pp.153~155 (2010)
65. Kawashima H, "Efficacy of plasma exchange and methylprednisolone pulse therapy on influenza-associated encephalopathy", J Infect, 51, pp.E53~56 (2005)
66. Munakata M, "Combined therapy with hypothermia and anticytokine agents in influenza A encephalopathy", Brain Dev, 22, pp.373~377 (2000)
67. Roberts C, "Steroid-sensitive post-viral inflammatory pneumonitis (PVIP)", Am J Respir Crit Care Med, 182, pp.1089~1090 (2010)
68. Martin-Loeches I, "Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection", Intensive Care Med, 37, pp.272~283 (2011)
69. Mady A, "Clinical experience with severe 2009 H1N1 influenza in the intensive care unit at King Saud Medical City, Saudi Arabia", J Infect Public Health, 5, pp.52~56 (2012)
70. Linko R, "Corticosteroid therapy in intensive care unit patients with PCR-confirmed influenza A(H1N1) infection in Finland", Acta Anaesthesiol Scand, 55, pp.971~979 (2011)
71. Han K, "Early use of glucocorticoids was a risk factor for critical disease and death from pH1N1 infection", Clin Infect Dis, 53, pp.326~333 (2011)
72. Maravi-Poma E, "Severe 2009 A", H1N1v influenza in pregnant women in Spain, 2011, pp.39, 945~951
73. Kawashima H, "Collaborating Study Group on Influenza- Associated Encephalopathy in Japan. Treatment of pandemic influenza A(H1N1) 2009-associated encephalopathy in children", Scand J Infect Dis, 44, pp.941~947 (2012)
74. Brun-Buisson C, "REVA-SRLF A", H1N1v 2009 Registry Group. Early corticosteroids in severe influenza A, Am J Respir Crit Care Med, pp.2011, 183[DOI]
75. Kim SH, "Corticosteroid treatment in critically ill patients with pandemic influenza A", H1N1 2009 infection: analytic strategy using propensity scores, 2011, pp.183, 1207~1214
76. Diaz E, "Corticosteroid therapy in patients with primary viral pneumonia due to pandemic (H1N1) 2009 influenza", J Infect, 64, pp.311~318 (2012)
77. Chong JL, "A case of acute respiratory distress syndrome associated with novel H1N1 treated with intravenous immunoglobulin G", J Microbiol Immunol Infect, 44, pp.319~322 (2011)
78. Gordon CL, "Pooled human immunoglobulin therapy in critically Ill patients with pandemic 2009 influenza A(H1N1) pneumonitis and immunoglobulin G2 subclass (IgG2) deficiency", Clin Infect Dis, 52, pp.422~426 (2011)
79. Iwanaga N, "An adult case of influenza-associated encephalitis successfully treated with high dose intravenous immunoglobulins", Kansenshogaku Zasshi, 86, pp.295~299 (2012)
80. Zhang R, "Clinical analysis of children with lymphoma complicated with severe pneumonia due to novel influenza A(H1N1) virus infection", Zhonghua Er Ke Za Zhi, 48, pp.610~613 (2010)
81. Terblanche M, "Statins and sepsis: multiple modifications at multiple levels", Lancet Infect Dis, 7, pp.358~368 (2007)
82. Vandermeer ML, "Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study", J Infect Dis, 205, pp.13~19 (2012)
83. Kwong JC, "Influenza morbidity and mortality in elderly patients receiving statins: a cohort study", PLoS One, 4, pp.e8087~ (2009)
84. Frost FJ, "Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins", Chest, 131, pp.1006~1012 (2007)
85. Brett SJ, "Pre-admission statin use and in-hospital severity of 2009 pandemic influenza A(H1N1) disease", PLoS One, 6, pp.e18120~ (2011)
86. Carrillo-Esper R, "Experience in the management of the severe form of human influenza A H1N1 pneumonia in an intensive care unit", Cir Cir, 79, pp.409~416 (2011)
87. Viasus D, "Effect of immunomodulatory therapies in patients with pandemic influenza A(H1N1) 2009 complicated by pneumonia", J Infect, 62, pp.193~199 (2011)
88. Patel P, "Use of therapeutic plasma exchange as a rescue therapy in 2009 pH1N1 influenza A: an associated respiratory failure and hemodynamic shock", Pediatr Crit Care Med, 12, pp.e87~89 (2011)